| Revenue growth | 14% YoY for FY26; 22% YoY for Q4FY26. |
|---|---|
| Margins | EBITDA margin improved from 23% in FY25 to 25% in FY26. |
| Demand visibility | Strong for complex injectables and new launches in US/Europe. |
| Management confidence | High, citing strong momentum in Cenexi and complex pipeline execution. |
Growth
FY26 Revenue up 14% to ₹64,307 Mn; Adj. PAT surged 50% to ₹10,455 Mn. Q4 revenue grew 22% YoY.
Outlook
Launched Liraglutide in US; signed complex oncology CDMO contract. Board recommended ₹20 dividend per share for FY26.
Risks
Lower uptake in select base business products; regulatory filing timelines and competitive pricing in US injectables.
Earnings Call filed with NSE, NSE: GLAND. Summary written with AI assistance from the document.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,115.60
- Market cap
- ₹51,411 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 45.5×Sector 47.4×
- Promoter holding
- 51.77%-0.06% QoQ
- FII holding
- 8.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Merger & Restructuring Worth ₹4.81 Cr
Gland Pharma is acquiring Gland Pharma USA Inc. for ₹4.81 Crore to streamline its corporate structure by making it a direct wholly-owned subsidiary.
- Value
- ₹4.81 Cr
Gland Pharma Acquisition Worth ₹4.76 Cr
Gland Pharma approved acquiring its step-down subsidiary, Gland Pharma USA Inc., from another wholly-owned subsidiary to streamline corporate structure. The transaction costs USD 5,01,208.
- Value
- ₹4.76 Cr
- Execution
- By October 31, 2026
Gland Pharma Employee Stock Options
Gland Pharma Limited granted 5,90,249 employee stock options to 124 employees under its ESOP 2025 scheme. These options are subject to specified vesting schedules and pricing.
Gland Pharma Legal & Regulatory
Gland Pharma paid fines totaling ₹1.40 Lakh to NSE and BSE for a technical regulatory non-compliance breach. The company has since ensured compliance with shareholder approval.
- Value
- ₹0.14 Cr
Gland Pharma Promoter Selling
Fosun Pharma Industrial Pte. Ltd., a promoter, sold 98,97,000 Gland Pharma shares in the open market. Its stake fell from 51.76% to 45.76%.
Gland Pharma Business Update
Gland Pharma announced that the USFDA completed a routine GMP inspection of its Visakhapatnam facility with zero Form 483 observations.